Literature DB >> 30414721

Inflammatory biomarkers in psychosis and clinical high risk populations.

Shannon Delaney1, Brian Fallon2, Armin Alaedini3, Robert Yolken4, Alyssa Indart3, Tianshu Feng5, Yuanjia Wang5, Daniel Javitt2.   

Abstract

BACKGROUND: Immunological, nutritional, and microbial factors have been implicated in the pathophysiology of schizophrenia, but the interrelationship among measures is understudied. In particular, an increase in the levels of the pro-inflammatory cytokine interleukin-6 (IL-6) is associated with all phases of the illness, and may be associated with other inflammatory markers. Vitamin D is a modulator of the immune system, and LPS antibodies are an indirect measure of gut barrier function. In this study we investigated potential contributing inflammatory mechanisms for IL-6 elevation.
METHODS: We compared the levels of vitamin D, C-reactive protein (CRP), antibodies to lipopolysaccharide (LPS), and IL-6 in children, adolescents and young adults with psychosis (n = 47), individuals at clinical high risk for psychosis (n = 17) and unaffected comparison controls (n = 33). Participants were diagnosed by a psychiatrist, using a structured interview, the MINI-Neuropsychiatric Interview. 25(OH)D was measured in serum using chemiluminescent micro particle immunoassay, and anti-LPS antibodies, CRP and IL-6 levels were measured by ELISA.
RESULTS: IL-6 and C-reactive protein levels were significantly elevated in the psychosis group relative to the unaffected control subjects. In the psychosis group, levels of IL-6 correlated positively with IgA anti-LPS antibodies and negatively correlated with vitamin D.
CONCLUSIONS: Our findings show a significant correlation between IL-6, anti-LPS antibodies and vitamin D deficiency in psychosis, suggesting the existence of multiple potential pathways related to IL-6 elevation in psychosis, and therefore multiple potential strategies for risk mitigation. Collectively these findings support hypotheses regarding interrelated inflammatory contributions to the pathophysiology of psychosis.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical high risk; IL-6; Inflammation; Psychosis; Vitamin D

Mesh:

Substances:

Year:  2018        PMID: 30414721     DOI: 10.1016/j.schres.2018.10.017

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  10 in total

1.  Pharmacological, physiological, and familial factors in propranolol-induced visions.

Authors:  Emmanuelle A D Schindler
Journal:  Neurol Clin Pract       Date:  2020-06

Review 2.  Recent advancements in biomarker research in schizophrenia: mapping the road from bench to bedside.

Authors:  Shivangi Patel; Dilip Sharma; Ankit Uniyal; Anagha Gadepalli; Vinod Tiwari
Journal:  Metab Brain Dis       Date:  2022-03-03       Impact factor: 3.655

3.  Zonulin-Dependent Intestinal Permeability in Children Diagnosed with Mental Disorders: A Systematic Review and Meta-Analysis.

Authors:  Birna Asbjornsdottir; Heiddis Snorradottir; Edda Andresdottir; Alessio Fasano; Bertrand Lauth; Larus S Gudmundsson; Magnus Gottfredsson; Thorhallur Ingi Halldorsson; Bryndis Eva Birgisdottir
Journal:  Nutrients       Date:  2020-07-03       Impact factor: 5.717

4.  The impact of the COVID-19 pandemic on negative symptoms in individuals at clinical high-risk for psychosis and outpatients with chronic schizophrenia.

Authors:  Gregory P Strauss; Kelsey I Macdonald; Ivan Ruiz; Ian M Raugh; Lisa A Bartolomeo; Sydney H James
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-04-21       Impact factor: 5.270

Review 5.  The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.

Authors:  Esmé Jansen van Vuren; Stephan F Steyn; Christiaan B Brink; Marisa Möller; Francois P Viljoen; Brian H Harvey
Journal:  Biomed Pharmacother       Date:  2021-01-01       Impact factor: 6.529

Review 6.  Understanding the Role of the Gut Microbiome in Brain Development and Its Association With Neurodevelopmental Psychiatric Disorders.

Authors:  Somarani Dash; Yasir Ahmed Syed; Mojibur R Khan
Journal:  Front Cell Dev Biol       Date:  2022-04-14

7.  Psychiatric Adverse Events Associated With Infliximab: A Cohort Study From the French Nationwide Discharge Abstract Database.

Authors:  Eve-Marie Thillard; Sophie Gautier; Evgeniya Babykina; Louise Carton; Ali Amad; Guillaume Bouzillé; Jean-Baptiste Beuscart; Grégoire Ficheur; Emmanuel Chazard
Journal:  Front Pharmacol       Date:  2020-04-22       Impact factor: 5.810

8.  Toll-like receptor 4 agonist and antagonist lipopolysaccharides modify innate immune response in rat brain circumventricular organs.

Authors:  Alejandra Vargas-Caraveo; Aline Sayd; Javier Robledo-Montaña; Javier R Caso; José L M Madrigal; Borja García-Bueno; Juan C Leza
Journal:  J Neuroinflammation       Date:  2020-01-06       Impact factor: 8.322

Review 9.  Gut dysbiosis in severe mental illness and chronic fatigue: a novel trans-diagnostic construct? A systematic review and meta-analysis.

Authors:  Jenelle Marcelle Safadi; Alice M G Quinton; Belinda R Lennox; Philip W J Burnet; Amedeo Minichino
Journal:  Mol Psychiatry       Date:  2021-02-08       Impact factor: 15.992

Review 10.  SARS-Cov-2 Damage on the Nervous System and Mental Health.

Authors:  Mohamed Said Boulkrane; Victoria Ilina; Roman Melchakov; Mikhail Arisov; Julia Fedotova; Lucia Gozzo; Filippo Drago; Weihong Lu; Alexey Sarapultsev; Vadim Tseilikman; Denis Baranenko
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.